Becton Dickinson, BioGX Seek FDA Emergency Clearance for COVID-19 Tests

Becton Dickinson and BioGX have submitted coronavirus diagnostic tests to the FDA for emergency use authorization.

The rapid diagnostic tests are designed for use on BD’s BD MAX molecular diagnostic platform, an automated system that can handle hundreds of tests per day. The tests take two to three hours to deliver results.

If authorized, the tests would increase the potential capacity to screen for COVID-19 by thousands of tests per day, BD said.